Medical Oncology

Papers
(The median citation count of Medical Oncology is 7. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
Oncotype DX testing does not affect clinical practice in stage IIa colon cancer60
How to ensure uninterrupted treatment of radiotherapy patients during delta variants of SARS-CoV-2 virus epidemic: the latest experience from Xi’an, China28
Innovation in cancer therapeutics and regulatory perspectives21
The inhibition of Panc1 cancer cells invasion by hAMSCs secretome through suppression of tyrosine phosphorylation of SGK223 (at Y411 site), c-Src (at Y416, Y530 sites), AKT activity, and JAK1/Stat3 si18
Mefenamic acid as a promising therapeutic medicine against colon cancer in tumor-bearing mice16
A linkage between effectual genes in progression of CRC through canonical and non-canonical TGF-β signaling pathways16
Impact of intravesical instillation of a novel biological response modifier (P-MAPA) on progress of non-muscle invasive bladder cancer treatment in a rat model16
Interferon regulatory factor-1 regulates cisplatin-induced apoptosis and autophagy in A549 lung cancer cells15
DNA methylation marker to estimate ovarian cancer cell fraction14
In silico bioinformatics analysis for identification of differentially expressed genes and therapeutic drug molecules in Glucocorticoid-resistant Multiple myeloma14
Combination of dasatinib and okadaic acid induces apoptosis and cell cycle arrest by targeting protein phosphatase PP2A in chronic myeloid leukemia cells13
Resveratrol triggers anti-proliferative and apoptotic effects in FLT3-ITD-positive acute myeloid leukemia cells via inhibiting ceramide catabolism enzymes13
Immune microenvironment-related gene mapping predicts immunochemotherapy response and prognosis in diffuse large B-cell lymphoma12
The combination therapy of Everolimus and anti-PD-1 improves the antitumor effect by regulating CD8+ T cells in bladder cancer12
Critical pathways of oral squamous cell carcinoma: molecular biomarker and therapeutic intervention12
Who should be treated with pembrolizumab in addition to standard of care in advanced cervical cancer?11
Bevacizumab in combination with paclitaxel and platinum for previously treated advanced thymic epithelial tumors10
SOX2 knockdown with siRNA reverses cisplatin resistance in NSCLC by regulating APE1 signaling9
Novel molecules as the emerging trends in cancer treatment: an update9
Glioblastoma recurrent cells switch between ATM and ATR pathway as an alternative strategy to survive radiation stress9
RNF144A exerts tumor suppressor function in breast cancer through targeting YY1 for proteasomal degradation to downregulate GMFG expression9
A prospective phase II clinical trial identifying the optimal regimen for carboplatin plus standard backbone of anthracycline and taxane-based chemotherapy in triple negative breast cancer8
ERCC6L is a biomarker and therapeutic target for non–small cell lung adenocarcinoma8
CDK9 inhibitors in multiple myeloma: a review of progress and perspectives8
Blue light induces ROS mediated apoptosis and degradation of AML1-ETO oncoprotein in Kasumi-1 cells8
Bioinformatics analysis of C3 in brain low-grade gliomas as potential therapeutic target and promoting immune cell infiltration7
Ambient air emissions of endocrine-disrupting metals and the incidence of hormone receptor- and HER2-dependent female breast cancer in USA7
IL-33 induces ADAMTS5 expression and cell migration in glioblastoma multiforme7
0.048919916152954